Edition:
India

Aslan Pharmaceuticals Ltd (ASLN.OQ)

ASLN.OQ on NASDAQ Stock Exchange Global Market

1.62USD
6 Aug 2020
Change (% chg)

-- (--)
Prev Close
$1.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,932
52-wk High
$8.18
52-wk Low
$0.35

Latest Key Developments (Source: Significant Developments)

Aslan Pharmaceuticals Reports Q2 Net Loss Of 4.0 Mln
Monday, 13 Jul 2020 

July 13 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ASLAN PHARMACEUTICALS LTD - NET LOSS FOR Q2 WAS US$4.0 MILLION VERSUS NET LOSS OF US$7.9 MILLION.  Full Article

Aslan Pharmaceuticals Files For Offering Of 4.6 Mln American Depositary Shares Representing 23.1 Mln Ordinary Shares
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS LTD FILES FOR OFFERING OF 4.6 MILLION AMERICAN DEPOSITARY SHARES REPRESENTING 23.1 MILLION ORDINARY SHARES - SEC FILING.  Full Article

Aslan Pharmaceuticals Acquires Full Global Commercial Rights For ASLAN004 From CSL
Friday, 31 May 2019 

May 31 (Reuters) - Aslan Pharmaceuticals::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR ASLAN004 FROM CSL.ASLAN PHARMACEUTICALS-AMENDED LICENSE AGREEMENT WITH CSL SO CO HAS FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE .COMMERCIALISE ASLAN004 IN ALL INDICATIONS.ASLAN PHARMACEUTICALS LTD SAYS AMENDED AGREEMENT REPLACES LICENSING AGREEMENT ASLAN AND CSL SIGNED IN MAY 2014.ASLAN PHARMACEUTICALS-UNDER TERMS OF AMENDED AGREEMENT, CO TO MAKE FIRST PAYMENT OF US$30 MILLION TO CSL UPON COMMENCEMENT OF A PHASE 3 STUDY OF ASLAN004.ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE UP TO US$95 MILLION OF REGULATORY MILESTONES.ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE $655 MILLION OF SALES MILESTONES, TIERED ROYALTIES ON NET SALES BETWEEN MID-SINGLE DIGITS AND 10%.  Full Article

Aslan Pharmaceuticals Qtrly Basic Loss Per Share $0.07
Friday, 22 Mar 2019 

March 22 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ASLAN PHARMACEUTICALS LTD QTRLY BASIC LOSS PER SHARE $0.07.ASLAN PHARMACEUTICALS - CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS TOTALED $28.9 MILLION AS OF DEC. 31, 2018 VERSUS $50.6 MILLION AS OF DEC. 31, 2017.  Full Article

BRIEF-Aslan Pharmaceuticals Reports First Quarter 2020 Financial Results

* ASLAN PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE